The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full-year 2024 financial results.

SOPA Images / Contributor / Getty Images Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders.